NS Pharma, Inc. — Biomedical Watch V2

Traitements4programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

4

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
NS-050/NCNP-03This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.	Myopathies	Phase 1/2	À vérifier	United States, Canada, Japan, South Korea, Turkey (Türkiye)	À vérifier
NS-089/NCNP-02This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly. The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.	Myopathies	Phase 2	À vérifier	United States, Australia, Canada, Japan, New Zealand, South Korea, Turkey (Türkiye)	À vérifier
NS-050/NCNP-03This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.	Myopathies	Phase 1/2	À vérifier	United States, Canada, Japan, South Korea, Turkey (Türkiye)	À vérifier
NS-089/NCNP-02This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly. The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.	Myopathies	Phase 2	À vérifier	United States, Australia, Canada, Japan, New Zealand, South Korea, Turkey (Türkiye)	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
NS-089/NCNP-02	Myopathies	Phase 2	NCT05996003	NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)	ACTIVE_NOT_RECRUITING
NS-050/NCNP-03	Myopathies	Phase 1/2	NCT06053814	NS-050/NCNP-03 in Boys With DMD (Meteor50)	ACTIVE_NOT_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.